Transforming Promising Ideas Into Clinical Reality​
Transforming Promising Ideas Into Clinical Reality​
Conditions We treat
Acute Coronary Syndrome
Heart failure
Arrhythmias
Alzheimer's Disease
Agitation
Migraine Headache
Inflammatory Bowel Disease
Dermatological Diseases
Active Cardiovascular Studies
*AEGIS-II :
Phase 3, to study CSL112 (human Apolipoprotein A1) infusion in subjects with ACS .
*HORIZON:
Impact of lipoprotein (a) lowering with TQJ230 on major CV events in patients with established cardiovascular disease.
*FINEARTS-HF:
Study to evaluate the efficacy and safety of finerenone on morbidity
and mortality in participants with heart failure (NYHA II-IV) and
* DIAMOND:
Study of Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment
of Heart Failure
*AIM-POWER
Artificial Intelligence Mobile Health Trial Of A Digital Platform To Optimize Guideline Directed Heart Failure Therapy Using Wearable Sensors.
*NODE 303:
Safety Study of Etripamil Nasal Spray for Patients with Paroxysmal Supraventricular Tachycardia.
*Heart FID:
Study to Investigate the Efficacy
and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure with Iron Deficiency.*
EMPACT-MI:
A streamlined, multicentre, randomised, parallel group, double-blind placebo-controlled superiority trial to evaluate the effect of EMPAgliflozin on hospitalisation for heart failure and mortality in patients with aCuTe Myocardial Infarction.
*AEGIS-II :
Phase 3, to study CSL112 (human Apolipoprotein A1) infusion in subjects with ACS .
*HORIZON:
Impact of lipoprotein (a) lowering with TQJ230 on major CV events in patients with established cardiovascular disease.
*FINEARTS-HF:
Study to evaluate the efficacy and safety of finerenone on morbidity
and mortality in participants with heart failure (NYHA II-IV) and
* DIAMOND:
Study of Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment
of Heart Failure
*AIM-POWER
Artificial Intelligence Mobile Health Trial Of A Digital Platform To Optimize Guideline Directed Heart Failure Therapy Using Wearable Sensors.
*NODE 303:
Safety Study of Etripamil Nasal Spray for Patients with Paroxysmal Supraventricular Tachycardia.
*Heart FID:
Study to Investigate the Efficacy
and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure with Iron Deficiency.*
EMPACT-MI:
A streamlined, multicentre, randomised, parallel group, double-blind placebo-controlled superiority trial to evaluate the effect of EMPAgliflozin on hospitalisation for heart failure and mortality in patients with aCuTe Myocardial Infarction.
Active Neurovascular studies
Active Neurovascular studies
OPC-34712:
A Phase 3, 12-Week, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-Arm, Fixed-dose Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer’s Type
(AURORA):Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa.
